Abstract

Aim : Clinical significance of Abolished PTEN expression to differentiate between malignant and hyperplastic endometrium as a diagnostic marker. Material and Methods : We used immunohistochemistry (IHC) to compare changes in PTEN expression in 50 endometrial biopsies that were diagnosed as endometrial hyperplasia without atypia, endometrial hyperplasia with atypia, and endometrial carcinoma and the control used was PTEN IHC for carcinoma prostate. The study uses PTEN as a marker to distinguish hyperplastic versus malignant endometrium in 50 endometrial biopsy and results were graded according to standard protocol. EH without atypia, EH with atypia, and endometrial carcinoma were the three categories for endometrial specimens. Results : PTEN was shown to be differentially expressed in atypical hyperplasia and EC in scores of 1+ and 0 or negative, while it was shown to be well expressed in hyperplasia without atypia in a score of 2+. Thirty of the fifty endometrial biopsy samples showed a score of 2+, seventeen showed 1+, and three showed 0 or negative. Conclusions : According to the current study PTEN expression is decreased in precancerous hyperplasia. PTEN IHC proved beneficial in screening precancerous hyperplasia lesions and diagnosing the earliest stage of endometrial carcinoma.

Description